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Abstract
Platelet-derived growth factor receptor β (PDGFRβ) is upregulated inmost of solid tumors. It is expressed by pericytes/
smooth muscle cells, fibroblast, macrophage, and certain tumor cells. Several PDGF receptor–related antagonists are
being developed as potential antitumor agents and have demonstrated promising antitumor activity in both preclinical
and clinical settings. Here, we produced a fully human neutralizing antibody, IMC-2C5, directed against PDGFRβ from
an antibody phage display library. IMC-2C5 binds to both human and mouse PDGFRβ and blocks PDGF-B from bind-
ing to the receptor. IMC-2C5 also blocks ligand-stimulated activation of PDGFRβ and downstream signalingmolecules
in tumor cells. In animal studies, IMC-2C5 significantly delayed the growth of OVCAR-8 and NCI-H460 human tumor
xenografts in nudemice but failed to show antitumor activities in OVCAR-5 and Caki-1 xenografts. Our results indicate
that the antitumor efficacy of IMC-2C5 is primarily due to its effects on tumor stroma, rather than on tumor cells di-
rectly. Combination of IMC-2C5 and DC101, an anti–mouse vascular endothelial growth factor receptor 2 antibody,
resulted in significantly enhanced antitumor activity in BxPC-3, NCI-H460, and HCT-116 xenografts, compared with
DC101 alone, and the trend of additive effects to DC101 treatment in several other tumor models. ELISA analysis
of NCI-H460 tumor homogenates showed that IMC-2C5 attenuated protein level of vascular endothelial growth
factor and basic fibroblast growth factor elevated by DC101 treatment. Finally, IMC-2C5 showed a trend of additive
effects when combined with DC101/chemotherapy in MIA-PaCa-2 and NCI-H460 models. Taken together, these re-
sults lend great support to the use of PDGFRβ antagonists in combination with other antiangiogenic agents in the
treatment of a broad range of human cancers.
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Introduction
Platelet-derived growth factors (PDGFs), a family of potent mitogens
for almost all mesenchymally derived cells, consist of four isoforms,
namely, A, B, C, and D [1,2]. These growth factors exert their cel-
lular effects through two structurally related tyrosine kinase receptors:
PDGF receptor α (PDGFRα) and PDGF receptor β (PDGFRβ).
Two ligands that bind PDGFRβ have been identified including
PDGF-B and PDGF-D. Binding of a ligand to the extracellular do-
main of PDGFRβ results in activation of the intrinsic receptor tyro-
sine kinase (RTK) activity and subsequent initiation of cytoplasmic
signal transduction pathways, in turn, leads to the migration, prolifer-
ation, and differentiation of PDGFRβ-expressing cells [1,2]. Platelet-
derived growth factor receptor β is expressed on surfaces of connective
tissue cells such as fibroblasts and smooth muscle cells (SMCs) and
on other cell types. In addition, various studies have showed that
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PDGF-B and PDGFRβ are also expressed and upregulated in most
of solid tumors [3].
Although both autocrine and paracrine PDGF signaling pathways
are involved in the development of various cancers, paracrine PDGF
signaling is commonly observed in epithelial cancers, especially for
PDGF-B/PDGFRβ signaling, where it triggers pericyte/SMC re-
cruitment and leads to maturation of tumor vessels, thereby affect-
ing tumor growth. Early evidences from PDGF-B and PDGFRβ
knockout mice revealed the roles of PDGF-B/PDGFRβ signaling
pathway in angiogenesis [4,5], an essential process for both tumor
growth and metastasis [6]. Through the production of PDGF-B, endo-
thelial cells (ECs) recruit PDGFRβ-expressing pericytes to angiogenic
vessels and the process further stimulates vascular SMC development
and, therefore, leads to vessel maturation [6,7]. Functional blockade
of PDGFRβ, but not PDGFRα, was found to prevent vascular
SMC accumulation, induce apoptosis of vascular ECs, and disrupt
glomerular capillary formation in neonatal mice [8]. Recent studies in-
dicated that PDGF signaling also regulates the expression of other an-
giogenic factors, such as basic fibroblast growth factor (bFGF) and
vascular endothelial growth factor (VEGF), in tumor stroma [9–12].
A number of “spectrum-selective” PDGFRβ kinase inhibitors are
currently being developed as potential antitumor agents and have dem-
onstrated promising therapeutic activity in both preclinical and clin-
ical settings, including imatinib mesylate (Gleevec/ST571), sunitinib
malate (Sutent/SU11248), and CP-673,451 [13–15]. Most of these
PDGFRβ-related inhibitors are multispecific, that is, in addition to
their activity on PDGFRβ, they also cross-react to several other ki-
nases, for example, imatinib mesylate to PDGFRα, BCR-ABL, and
c-kit, and sunitinib malate to VEGF receptor (VEGFR), c-kit, and
FLT3. As a consequence, the contribution of PDGFRβ blockade
in tumor growth inhibition could not be clearly defined with these
compounds. Previously, we reported identification of an anti–mouse
PDGFRβ antibody, 1B3, and evaluation of its efficacy in animal study
as monotherapy and its ability to enhance the antitumor and anti-
angiogenic activities of an antibody to mouse VEGFR2, DC101 [16].
In this study, we described the identification and characterization of a
fully human antibody, IMC-2C5, from a naive phage display library.
IMC-2C5 binds to both human (hPDGFRβ) and mouse PDGFRβ
(mPDGFRβ), thus can be used as an excellent reagent for examining
the antitumor efficacy of a specific PDGFRβ antagonist in mouse
models of human tumor xenografts because the antibody would
block the receptors expressed on both human tumor cells and mouse
stromal cells. We studied the antitumor activity of IMC-2C5, used
alone or in combination with DC101 and DC101 plus chemother-
apy, in several models. We also tested the effects of IMC-2C5 and
DC101 on the expression of several tumor-associated growth factors
in the treated tumors. Our results indicate that the antitumor efficacy of
a specific PDGFRβ antagonist may be primarily due to its effects on
tumor stroma rather than on tumor cells directly. Further, an anti-
PDGFRβ antibody is most effective when used in combination with
other antitumor agents, including antiangiogenic compounds and
conventional chemotherapeutics.
Materials and Methods
Reagents and Cell Lines
Recombinant human and mouse PDGFRβ extracellular domain-
Fc fusion protein, and their ligand, recombinant PDGF-B, were pur-
chased from R&D Systems, Inc. (Minneapolis, MN). Human tumor
cell lines, including OVCAR-5 and OVCAR-8 (ovarian), BxPC-3
and MIA-PaCa-2 (pancreatic), HCT-116 (colon), NCI-H460 and
NCI-H292 (non–small cell lung carcinoma, NSCLC), Caki-1 (renal),
and Detroit-562 (head and neck squamous cell), and murine cell
lines, NIH/3T3 (embryonic fibroblasts) and D122 (Lewis lung car-
cinoma), were obtained from the American Type Culture Collection
(Manassas, VA). All cells were maintained in Dulbecco’s modified
Eagle medium (Invitrogen, Carlsbad, CA) containing 10% fetal calf
serum (HyClone, Logan, UT) at 37°C in 5% CO2.
Identification of Anti-hPDGFRβ Antibodies from a Phage
Display Library
A human Fab phage display library containing 3.7 × 1010 clones
[17] was used to screen for anti-hPDGFRβ antibodies following a
previously described procedure [16], using hPDGFRβ/Fc as the bait.
Individual phage clones recovered after the second and third rounds
of selections were examined for binding to immobilized hPDGFRβ/
Fc and for blocking of hPDGFRβ/PDGF-B interaction by ELISA
previously described [18,19]. Selected clones were also tested for
binding to mPDGFRβ/Fc.
Full-length IgG Antibody Cloning and Expression
The DNA sequences encoding the heavy- and light-chain variable
genes for the leading clone, IMC-2C5, were amplified by polymerase
chain reaction and cloned into an expression vector containing
human κ light-chain constant region and human γ1 heavy-chain
constant region. The expression vector was transfected into NS0
myeloma cells, and stable clones of IMC-2C5–expressing cells were
selected. The cells were grown in serum-free medium, and the full-
length IMC-2C5 IgG was purified from the cell culture supernatant
by protein A affinity chromatography (Poros A; Applied Biosystems,
Foster City, CA).
Quantitative Receptor Binding and Blocking Assays
In the binding assay, various amounts of IMC-2C5 IgG and 1B3
IgG, an antibody specific to mPDGFRβ, were added to hPDGFRβ
or mPDGFRβ-coated plates (50 μl at 1 μg/ml) and incubated at
room temperature (RT) for 1 hour, after which the plates were washed
three times with phosphate-buffered saline containing 0.1% Tween 20
(PBST). The plates were then incubated at RT for an additional 1 hour
with a goat anti–human-κ antibody–horseradish peroxidase (HRP)
conjugate (Jackson ImmunoResearch, West Grove, PA). The plates
were washed and developed as previously described [16]. In the block-
ing assay, various amounts of purified antibodies were first mixed
with a fixed amount of hPDGFRβ or mPDGFRβ (50 ng at 0.5 μg/ml)
and incubated at RT for 30 minutes. The mixture was then trans-
ferred to 96-well plates precoated with PDGF-B (0.5 μg/ml) and in-
cubated at RT for 1 hour. After washing three times with PBST, the
plates were incubated with a goat anti–human Fc antibody–HRP con-
jugate (Jackson ImmunoResearch) for 1 hour and developed as de-
scribed. IC50, the antibody concentration that yielded 50% blockade
of PDGFRβ from binding to its ligand, was determined.
Antibody Affinity Determination
The binding kinetics of IMC-2C5 to hPDGFRβ and mPDGFRβ
were measured using a BIAcore 3000 biosensor (BIACORE, Inc.,
Uppsala, Sweden). Briefly, hPDGFRβ or mPDGFRβ were immobi-
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lized onto a sensor chip, and IMC-2C5 was injected at concentrations
ranging from 1.5 to 100 nM. Sensorgrams were obtained at each
concentration and were evaluated using the program, BIA Evalua-
tion 2.0. The affinity constant, K d, was calculated from the ratio
of dissociation rate (koff ) to association rate (kon).
Flow Cytometric Analysis of PDGFRβ Surface Expression in
Tumor Cells
A panel of human tumor cell lines and two murine cell lines were
examined for the expression of PDGFRβ through a flow cytometric
analysis, including OVCAR-5, OVCAR-8, Caki-1, NCI-H292, NCI-
H460, BxPC-3, MIA-PaCa-2, Detroit-562, HCT-116, NIH/3T3,
and D122. Briefly, the cells were aliquoted into wells of a 96-well plate
at ∼1 × 106 per well, incubated with IMC-2C5 (10 μg/ml) at 4°C
for 1 hour, followed by incubation with an anti–human Fc antibody–
fluorescein isothiocyanate conjugate (Jackson ImmunoResearch) for
an additional hour at 4°C. After several washes with cold phosphate-
buffered saline, the cells were analyzed using a Guava EasyCyte Plus
flow cytometer (Guava Technologies, Hayward, CA).
Phosphorylation Assay
Caki-1, NIH/3T3, and D122 cells were plated onto 6-cm dishes
and grown to 70% to 80% confluence, after which the cells were
washed twice with phosphate-buffered saline and cultured overnight
in serum-free medium. The cells were first incubated with various
amount of IMC-2C5 at RT for 30 minutes, followed by stimulation
with PDGF-B at 37°C for 15 minutes. The cells were then lysed
in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton
X-100, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM
Na3VO4, 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 1 μg/ml apro-
tinin) for 1 hour, followed by centrifugation of the lysate at 12,000 rpm
for 10 minutes at 4°C. The receptors were immunoprecipitated from
the cell lysate supernatant by an anti-hPDGFRβ or anti-mPDGFRβ
antibody (R&D Systems, Inc.), followed by the addition of 20 μl of
ProA/G sepharose beads. The precipitated receptor proteins were re-
solved on a 4% to 12% NuPAGE Bis-Tris gel and transferred to a
polyvinylidene difluoride membrane. Phospho-PDGFRβ protein was
detected on the blot using an anti–phospho tyrosine antibody–HRP
conjugate (Santa Cruz Biotech, Santa Cruz, CA). Total receptor pro-
teins loaded on the gel were assayed with an antibody to PDGFRβ.
To study the downstream signaling, the cell lysates from the previ-
ously mentioned treatment were resolved by a 4% to 12% NuPAGE
Bis-Tris gel. Phosphorylated Akt and p44/42 mitogen-activated pro-
tein kinase (MAPK) were detected using an anti–phospho-Akt and
an anti–phospho-p44/p42 MAPK antibody, respectively (eBioscience,
San Diego, CA).
Human Tumor Xenograft Models
Athymic (nu/nu) mice (female, 7-8 weeks of age) were housed for
7 to 10 days before xenograft implantation. Each mouse was injected
subcutaneously with 3 to 10 × 106 cells of various tumor cells. When
tumors reached 200 to 400 mm3, mice were randomized into groups
of 10 or 12 animals each and treated by intraperitoneal (i.p.) injec-
tion of the antibody or antibody combination, twice at 60 mg/kg
or three times 40 mg/kg per week, respectively, for a total dose of
120 mg/kg of each antibody per week. Human IgG and/or USP sa-
line was used as controls. Chemotherapy drugs, paclitaxel (20 mg/kg)
or gemcitabine (500 mg/kg), were dosed i.p. once a week, which
started 1 day before antibody therapy. Tumor sizes and mouse body
weight were measured twice a week. Tumor volume was calculated
using the formula: π/6 × (length × width2), where length = longest
diameter and width = diameter perpendicular to length. A percentage
of mean tumor volume of a treatment group versus that of the control
group (T /C%) was calculated. Statistic analysis was performed by
repeated-measures analysis of variance (ANOVA).
Tumor-Associated Growth Factors in Tumor Homogenates
Athymic nude mice bearing xenografted NCI-H460 tumors of
∼250-mm3 size were randomized and divided into four treatment
groups and were treated by i.p. injections three times a week of
USP saline, IMC-2C5 (40 mg/kg), DC101 (40 mg/kg), or IMC-
2C5 (40 mg/kg) plus DC101 (40 mg/kg). Tumor sizes were mea-
sured twice a week. At the days 3, 7, and 14, six animals from each
group were killed by CO2 asphyxiation, and their tumors were har-
vested. Tumors were homogenized with a Kinematica Polytron ho-
mogenizer in RIPA Lysis Buffer Kit (Santa Cruz Biotech). After
incubation and centrifugation, the supernatants were aliquoted and
stored at −80°C. Total protein contents of the homogenates were
estimated with the Pierce BCA kit. All enzyme-linked immunosor-
bent assay (ELISA) analysis was performed by coating capture anti-
bodies (R&D Systems, Inc.) on ELISA plates. After applying the
tumor homogenates, captured proteins were detected with biotin-
ylated antibodies (R&D Systems, Inc.) and then streptavidin–HRP
conjugate (Pierce). The levels of PDGF-B, VEGF, hypoxia-inducible
factor 1α-subunit, and bFGF were estimated from the titrations of
standard proteins (R&D Systems, Inc.).
Results
Identification of PDGFRβ Inhibitory Antibody Specific to
Both Human and Mouse Receptors from a Fab Phage
Display Library
A large naive human Fab phage display library containing 3.7 ×
1010 clones from Dyax was used to select antibodies directed against
human PDGFRβ. Phage clones from the second and third rounds of
affinity selection were randomly picked and tested for hPDGFRβ
binding and blocking activities by ELISA. From preliminary screen-
ing, IMC-2C5, the clone with the strongest blocking activity was
identified and converted into a full IgG and expressed in mammalian
cells. Purified IMC-2C5 antibody was then evaluated for its binding
activity to hPDGFRβ and mPDGFRβ, and its efficiency in blocking
hPDGFRβ and mPDGFRβ from binding to PDGF-B, in compari-
son with 1B3, an antibody specific to mPDGFRβ. As expected, 1B3
only bound to immobilized mPDGFRβ, but not to hPDGFRβ,
whereas IMC-2C5 bound to both human and mouse PDGFRβ
(Figure 1, A and B). Binding kinetic analysis by surface plasmon res-
onance on a BIAcore instrument revealed that the affinities of IMC-
2C5 for binding to hPDGFRβ and mPDGFRβ were 0.014 and
0.061 nM, respectively, whereas 1B3 binds to mPDGFRβ with an
affinity of 0.09 nM [16]. No cross-reactivity of IMC-2C5 with hu-
man and mouse PDGFRα was detected by ELISA (data not shown).
In the blocking assay, IMC-2C5 inhibited hPDGFRβ from binding
to its ligand PDGF-B with an IC50, the antibody concentration that
yielded 50% blocking activity, of 0.55 nM (Figure 1C ), whereas it
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showed an IC50 of 0.35 nM in blocking mPDGFRβ binding to
PDGF-B, similar to that of 1B3 (Figure 1D).
IMC-2C5 Binds to Cell Surface–Expressed PDGFRβ, Inhibits
PDGF-B–Stimulated Receptor Phosphorylation and
Downstream Signaling in Cell-Based Assay
In a flow cytometric analysis, various human and mouse tumor
cell lines were used, including several human cell lines (OVCAR-5,
OVCAR-8, Caki-1, NCI-H460, NCI-H292, HCT-116, Detroit-562,
MIA-PaCa-2, and BxPC-3) and two murine cell lines (NIH/3T3 and
D122). The results showed that Caki-1, OVCAR-8, HCT-116, NIH/
3T3, and D122 were strongly stained by IMC-2C5, whereas NCI-
H460 and Detroit-562 were weakly stained, and the other cell lines
did not yield any staining with IMC-2C5 (Table 1).
In the receptor phosphorylation assay, IMC-2C5 inhibited PDGF-
B–stimulated receptor phosphorylation inCaki-1, NIH/3T3 andD122
cells in a dose-dependent manner. At a concentration of 1.8 μg/ml
(12 nM), IMC-2C5 antibody completely inhibited PDGF-B–stimulated
receptor phosphorylation in Caki-1 cells (Figure 2A). In the two mu-
rine cell lines, NIH/3T3 and D122, IMC-2C5 inhibited PDGFRβ
phosphorylation with an IC50 of ∼1.7 μg/ml (11 nM; Figure 2, B
and C ). The antibodies also potently inhibited PDGF-B–stimulated
phosphorylation of both Akt and p44/42 MAP kinase in Caki-1 cells
(Figure 2A). In the Boyden chamber migration assay, IMC-2C5 sig-
nificantly inhibited PDGF-B (at 30 ng/ml)–stimulated cell migration
of PDGFRβ-expressing NCI-H460, OVCAR-8,WS-1, and U-118MG
cells (data not shown).
Antitumor Activity of IMC-2C5 as a Monotherapy Agent in
Tumor Xenograft Models
Four human tumor xenograft models, including two ovarian car-
cinomas (OVCAR-5 and OVCAR-8), an NSCLC (NCI-H460), and
a renal carcinoma (Caki-1), were used to assess the antitumor activity
of IMC-2C5, in comparison with 1B3 antibody. IMC-2C5 demon-
strated significant antitumor activity in both OVCAR-8 and NCI-
H460 xenograft models: it almost completely blocked the growth
of OVCAR-8 tumors by the end of treatment with a T /C of 39%
Table 1. Summary of Anti-PDGFRβ Antibodies in Monotherapy.
Xenograft Tumor Volume – 1B3 Tumor Volume – 2C5 PDGFRβ
Expression
T /C% P T /C% P MFI*
OVCAR-8 43 .0022 39 .0014 5
NCI-H460 60 .0235 60 .0115 2
OVCAR-5 92 .7 84 .06 1
Caki-1 78 .1004 91 .6303 10
BxPC-3 ND† ND 116 .4377 1
MIA-PaCa-2 ND ND 70 .0554 1
HCT-116 ND ND 96 .5799 6
Detroit-562 ND ND 75 .2405 3
NCI-H292 ND ND 75 .3581 1
*Mean fluorescence intensity (MFI) using IMC-2C5 as the detection agent as determined by
FACS analysis. A value of 1 indicates no apparent expression detected when compared with the
control sample that was stained by a normal human IgG.
†Not done.
Figure 1. IMC-2C5 binds to human and mouse PDGFRβ and efficiently blocks PDGF-B/PDGFRβ interaction. 1B3, an antibody specific to
mouse PDGFRβ, was used as a control. The binding activities of IMC-2C5 to immobilized human and mouse PDGFRβ were assayed by
ELISA. (A) Binding to hPDGFRβ. (B) Binding to mPDGFRβ. (C) Blocking PDGF-B binding to hPDGFRβ. (D) Blocking PDGF-B binding to
mPDGFRβ. Data represent the mean ± SD of triplicate determinations.
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(P = .0014; Figure 3A) and significantly slowed the growth of NCI-
H460 tumors with a T /C of 60% (P = .0115; Figure 3B). Conversely,
IMC-2C5 failed to show significant antitumor activity in OVCAR-5
xenografts (T /C 84%, P = .06) and Caki-1 xenografts (T /C 91%,
P = .6303; Figure 3, C and D). Although IMC-2C5 is capable of
blocking PDGFRβ expressed by both tumor and host stroma cells,
treatment of IMC-2C5 did not yield better inhibitory effect in tumor
growth comparing with 1B3 (Table 1). In addition, antitumor effects
of both 1B3 and IMC-2C5 did not seem to correlate directly with the
expression level of PDGFRβ by tumor cell lines (Table 1). IMC-2C5
treatment did not cause any overt toxicity, including changes in body
weight and animal behavior, in all four models examined.
Enhancement of Antitumor Activity of an Anti-VEGFR2
Antibody, DC101, by IMC-2C5 in Tumor Xenograft Models
IMC-2C5 was evaluated for its ability to enhance the antitumor ac-
tivity of an anti–mouse VEGFR2 antibody, DC101, in several tumor
xenograft models, including BxPC-3, NCI-H460, HCT-116, MIA-
PaCa-2, NCI-H292, and Detroit-562. As previously described [20],
treatment with DC101 significantly inhibited the growth of all tu-
mor xenografts (Figure 4, A–F ). As a monotherapy agent, however,
IMC-2C5 showed no effect or very limited effect in the inhibition of
tumor growth in five of six tumor models except in NCI-H460 xeno-
grafts (T /C 60%, P < .05). However, coadministration of IMC-2C5
and DC101 resulted in a greater inhibition of tumor growth than
either of the antibodies alone in all six tumor xenograft models, al-
though only three of them reached statistical significance.
In the BxPC-3 xenografts (Figure 4A), combination of IMC-2C5
and DC101 led to significantly enhanced tumor inhibition on day 31:
T /C was 21% in mice that received antibody combination (P =
.0001) compared with that of 47% in mice treated with DC101
alone (P = .0027). Treatment of USP saline and IMC-2C5 groups
was terminated at day 31, and treatments of DC101 and IMC-
2C5 plus DC101 groups were continued up to day 56. Repeated-
measures ANOVA through day 52 showed that the efficacy of the
combination group was significantly higher than that of the DC101
alone (P < .0001). In addition, three partial tumor regressions were
observed in the combination group versus only one regression with
DC101 monotherapy at the end of treatment. In the NCI-H460
xenografts (Figure 4B), the T /C of IMC-2C5/DC101 treatment at
day 15 was 22% (P < .0001), whereas it was 32% for DC101 mono-
therapy (P = .0003). Repeated-measures ANOVA through day 21
showed that the efficacy of the combination therapy was significantly
higher than DC101 monotherapy (P < .0001). In the HCT-116 xeno-
grafts (Figure 4F), the T /C of the combination group at the end of
study (day 29) was 36% (P = .0001) compared with that of 44% in
mice treated with DC101 alone (P = .0001). Statistical analysis
showed that the efficacy of the antibody combination was significantly
higher than that of DC101 alone (P = .0010). Greater inhibitions of
tumor growth by the combination therapy over DC101 monotherapy
were also observed inMIA-PaCa-2, NCI-H292, andDetroit-562 xeno-
grafts (Figure 4, C–E), although the differences between two groups
at the end of the study failed to reach statistical significance, with P val-
ues of .4164 on day 46 for MIA-PaCa-2 tumors, .3832 on day 36 for
NCI-H292 tumors, and .1146 on day 74 for Detroit-562 tumors.
Effects in Expression of Tumor-Associated Growth Factors by
IMC-2C5 in NCI-H460 Tumor Xenografts
To evaluate the effects of antibody treatment on the expression of
tumor-associated growth factors during tumor development, six tu-
mor xenografts of NCI-H460 from each treatment group were har-
vested after 3, 7, and 14 days of treatment and were homogenized.
Tumor sizes on day 12 were 1442 ± 171, 1492 ± 274, 749 ± 119,
and 631 ± 85 mm3 for saline, IMC-2C5, DC101, and DC101/
IMC-2C5, respectively. The difference of tumor growth inhibition
between DC101 and IMC-2C5/DC101 was not significant. Tumor
lysates were then tested for the total protein contents and the levels
of PDGF-B, VEGF, HIF-1α, and bFGF (Figure 5, A–D). The re-
sults showed that IMC-2C5 treatment elevated the protein levels
of PDGF-B compared with the saline control on days 7 and 14 (Fig-
ure 5A). In addition, IMC-2C5 plus DC101 group had a significantly
higher level of PDGF-B compared with DC101 alone on day 14. As
previously observed, DC101 treatments, either alone or in combina-
tion, elevated the expression of VEGF at all time points (Figure 5B).
However, on day 14, the antibody combination–treated tumors had
a much-reduced level of VEGF compared with DC101 alone treat-
ment. The contents of proteins that are not directly related to the
antibodies used in the study, including HIF-1α and bFGF, were also
evaluated. The HIF-1α levels were significantly higher in DC101
treatment groups on days 7 and 14 compared with that in the saline
Figure 2. IMC-2C5 antibody inhibits PDGF-B–stimulated receptor
phosphorylation and downstream signaling. Caki-1 (human), NIH/3T3,
and D122 (mouse) cells were treated as described in the Materials
and Methods section. The receptors were immunoprecipitated from
the cell lysate supernatant by anti-PDGFRβ antibodies and were
resolved by SDS-PAGE. The amount of phosphorylated PDGFRβ
(p-PDGFRβ) was assessed through immunoblot analysis using an
anti–phospho-tyrosine antibody–HRP conjugate. The amounts of total
PDGFRβ proteins loaded in each lane were confirmed by detecting
with antibodies to PDGFRβ. To analyze the effect of IMC-2C5on down-
stream signaling, the cell lysates were resolved by SDS-PAGE. Phos-
phorylated Akt and p44/42 MAP kinase, as well as total loadings of
Akt and p44/42 MAP kinase, were then detected using Western blot
analysis. (A) Caki-1. (B) NIH/3T3. (C) D122.
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control (Figure 5C ). DC101 alone group also showed a significantly
higher level of bFGF on day 7 compared with the saline and the
combination groups (Figure 5D).
Additive Effect of IMC-2C5 on Antitumor Activity of DC101
Plus Chemotherapy in Tumor Xenograft Models
IMC-2C5 was further evaluated for its ability to enhance the anti-
tumor activities of DC101/chemotherapy combination in two tu-
mor models, including NCI-H460 and MIA-PaCa-2 xenografts.
In the triple combination studies, larger tumors, at sizes of 350 to
400 mm3, were used to reduce the tumor sensitivity to DC101/
chemotherapy. In the NCI-H460 tumor model, DC101/paclitaxel
and DC101/paclitaxel plus IMC-2C5 treatments both significantly
inhibited the tumor growth with P values of .0038 and .0018 on
day 19, respectively (Figure 6A). The control group was terminated
on day 19, and treatments of DC101/paclitaxel and DC101/paclitaxel
plus IMC-2C5 were continued up to day 43. A separation of the
tumor growth between the two groups was observed with smaller
tumor sizes for DC101/paclitaxel plus IMC-2C5 group, although
repeated-measures ANOVA through day 43 showed that the im-
provement in tumor inhibition of the triple combination was not
significant compared with that of the DC101/paclitaxel treatment
(P = .2693).
In the MIA-PaCa-2 model, the analysis on day 37 showed that
DC101/gemcitabine treatment, with T /C of 44%, was not statisti-
cally significant (P = .0769) compared with the saline control group.
DC101/gemcitabine plus IMC-2C5, however, yielded a T /C of 34%,
which reached statistical significance (P = .0270; Figure 6B). The
control group was terminated on day 37, and treatments of DC101/
gemcitabine and DC101/gemcitabine/IMC-2C5 were continued up
to day 49. At the end of the study, the average tumor volume in
DC101/gemcitabine/IMC-2C5 group was only approximately 50%
of the size of that in theDC101/gemcitabine group. Repeated-measures
ANOVA through day 43, however, showed that the difference between
the two groups was not statistically significant (P = .2399).
Discussion
Recent studies have shown the complex interplay between various
tumor-associated growth factor/receptor pathways in promoting tu-
mor angiogenesis, growth, and metastasis [9,11]. As a consequence,
the field of targeted cancer therapy is being rapidly expanded from
simply targeting cancer cells directly to also targeting their supporting
Figure 3. IMC-2C5 antibody inhibits tumor growth as a monotherapy agent in xenograft models. nu/nu mice (female, 7-8 weeks) were
injected subcutaneously with ∼5 × 106 tumor cells: OVCAR-8 (A), NCI-H460 (B), OVCAR-5 (C), or Caki-1 (D). When tumors reached 250
to 300 mm3, mice were randomized into two treatment groups (n = 10 or 12) following a treatment schedule: antibodies at 60 mg/kg
twice weekly (A, C, and D) or three times a week at 40 mg/kg (B) by i.p. injection. Human IgG and USP saline were used as controls.
Tumor volumes of mice were recorded twice a week. Results shown are the mean ± SEM.
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cells in tumor microenvironment, such as EC, pericytes/vascular
SMC, and stromal fibroblasts [21]. Early antiangiogenic therapy in
cancer drug development focused mainly on ECs, such as a blockade
of VEGFR/VEGF signaling. For example, a variety of animal studies
have shown that treatment with an anti-VEGF antibody, bevacizumab,
or an anti–mouse VEGFR2 antibody, DC101, was efficacious in anti-
tumor and antiangiogenesis in xenograft models in mice, including a
significant life span extension [22–24]. Extended treatment with these
antibodies, however, has been shown to result in a phenotypic resis-
tance to VEGF/VEGFR inhibition owing to the up-regulation
of other proangiogenic growth factors including HIF-1α, PDGF,
and bFGF [22,25–27]. The resistance of tumor blood vessels to
VEGF/VEGFR inhibition was also observed in tumors treated with
the tyrosine kinase inhibitors such as SU5416 [28]. To this end, a
Figure 4. IMC-2C5 enhances the antitumor activity of an anti-VEGFR2 antibody, DC101. Athymic nude mice bearing xenografted tumors
of 200 to 300 mm3 size were randomized and divided into four treatment groups (n = 12 per group) and were treated by i.p. injections
three times a week with USP saline, IMC-2C5 (40 mg/kg), DC101 (40 mg/kg), or IMC-2C5 plus DC101 (40 mg/kg each). (A) BxPC-3. (B)
NCI-H460. (C) MIA-PaCa-2. (D) NCI-H292. (E) Detroit-562. (F) HCT-116. Results shown are the mean ± SEM.
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number of studies have revealed that a blockade of PDGF/PDGFR
signaling with multi–tyrosine kinase inhibitor such as imatinib led
to downregulate bFGF expressed by stromal fibroblasts [10] and abro-
gate VEGF production in gastrointestinal stromal tumors [29]. Taken
together, these findings demonstrate the complexity of multiple pro-
cesses in tumor microenvironment during the tumor development and
the complex survival mechanisms of tumors to treatment.
Accumulating evidence suggests that simultaneously targeting can-
cer as well as their supporting (co-opted) cells may lead to enhanced
anticancer efficacy [21,28,30,31]. Among various strategies to target
tumor co-opted cells, agents direct against molecules (receptors) ex-
pressed on pericyte/vascular SMC and stromal fibroblasts, such as
PDGFRβ, are being actively pursued [32–34]. Platelet-derived growth
factor receptor β has been shown primarily responsible for pericyte
recruitment to capillaries, development of SMCs in vessels and of
mesangial cells in the kidney [4,35]. Under pathological conditions,
the PDGF-B/PDGFRβ signaling pathway has been implicated in
several tumor-associated processes including stimulation and regula-
tion of tumor angiogenesis and recruitment and regulation of tumor
fibroblasts (for details, see review by Ostman [3]). Recently, Rolny
et al. [36] showed that PDGFRβ is expressed on CD31+CD41+
VEGFR2+ hematopoietic/endothelial precursors, or hemangiopre-
cursors. Activation of PDGFRβ on these hemangioprecursors accel-
erates differentiation of ECs and vascular remodeling. In another
report, Song et al. [37] identified a subset of PDGFRβ+/sca1+ pro-
genitor perivascular cells that could be recruited from bone marrow
to perivascular sites in tumors. Through paracrine mechanism involv-
ing growth factors, such as PDGF-B, produced by ECs, such pre-
cursors could differentiate into mature pericytes and regulate vessel
stability and survival in tumors. Specific inhibition of PDGFRβ signal-
ing with a neutralizing antibody to the receptor eliminates PDGFRβ+
progenitor perivascular cells and mature pericytes around tumor vessels,
leading to increased EC apoptosis [8,37,38]. Taken together, these
findings suggest that PDGF-B/PDGFRβ pathway may represent an
Figure 5. IMC-2C5 affects the levels of expression of several tumor-associated growth factors in the antibody treated tumors. NCI-H460
cell suspension (5 × 106 cells per mouse), was subcutaneously injected into female athymic mice. When tumors reached ∼250 mm3,
mice were randomized and divided into four treatment groups and were treated by i.p. injection three times a week with USP saline,
IMC-2C5 (40 mg/kg), DC101 (40 mg/kg), or IMC-2C5 plus DC101 (40 mg/kg each). Six tumors from each treatment group were harvested
at days 3, 7, and 14 and were homogenized. ELISA was performed to estimate the levels of PDGF-B (A), VEGF (B), HIF-1α (C), and bFGF
(D) in each treated tumors. Results shown are the mean ± SEM. *P < .05 of treatment group versus saline at the same time point,
unless indicated otherwise.
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excellent target for cancer therapy through both direct antitumor
and antiangiogenesis mechanisms. To this end, a number of selec-
tive PDGFRβ kinase inhibitors, including imatinib mesylate and
sunitinib malate [13,14,39], have demonstrated promising thera-
peutic activity in both preclinical and clinical settings. However, be-
cause these small molecule antagonists are not truly (or restrictively)
specific to the receptor, it is not possible to dissect out the specific
contribution to the overall antitumor activity as well as the poten-
tial toxicities that may be associated with PDGFRβ inhibition.
Here, we generated a high-affinity fully human neutralizing anti-
body that binds to both human and mouse PDGFRβ and efficiently
neutralizes PDGF-B–induced receptor activation and downstream
signaling (Figures 1 and 2). This unique species cross-reactive feature
of the antibody enabled us to investigate the antitumor activity of a
specific PDGFRβ blockade approach in mouse models of human tu-
mor xenografts because the antibody would inhibit the receptor ac-
tivity on both human tumor cells and host stromal cells, a situation
similar to that in the treatment of patients in clinical practice. We
previously reported the generation of an anti-mPDGFRβ antibody,
1B3, and demonstrated that 1B3 modestly inhibited the growth of
a certain type of human tumor xenografts [16]. Here, we compared
the antitumor effect of targeting host PDGFRβ alone (by 1B3) with
that of targeting PDGFRβ on both host and human tumor cells in
four human xenograft models. To our surprise, the IMC-2C5 was
not more efficacious than 1B3, in all the four models tested, includ-
ing those tumors with a high-level expression of human PDGFRβ
(Figure 3). Further, there seems no direct correlation between the
level of PDGFRβ expression on tumor cells and the antitumor activ-
ity of IMC-2C5 (Table 1). Conversely, it was unclear if PDGFRβ
expressed by the tumor cells was activated in the xenografts. Kim
et al. [40] found that PDGFR activation occurs only on PC-3MM2-
MDR cells growing in the bone but not on tumor cells growing
in the muscles, indicating that PDGFR activation depends on the
cross talk between tumor cells and host microenvironment. It is per-
tinent to note that, whereas PDGF-B strongly activates PDGFRβ
and its downstream signaling pathways (including MAPK and Akt)
and stimulates migration of PDGFRβ-expressing cells, it did not
manifest any significant mitogenic activity in vitro in promoting
growth and proliferation of the same types of tumor cells (our un-
published data). In the animal study with PC-3MM2-MDR model,
imatinib treatment increased apoptosis of tumor-associated ECs but
not tumor cells, although inhibited phosphorylation of PDGFR was
obtained on both cell types, indicating a complex downstream signal-
ing of PDGFRβ [40]. Taken together, these observations suggest that
the antitumor activity of the anti-PDGFRβ antibodies is perhaps pri-
marily due to their effects on PDGFRβ-expressing cells in tumor
stroma rather than on tumor cells directly.
As a single agent, PDGFR-selective RTK inhibitor (such as imatinib)
has not yet been proven efficacious in PDGFR-expressing solid tu-
mors in several phase 2 clinical trails [41]. However, combined inhi-
bition of both VEGF and PDGF signaling pathways with so-called
“spectrum-selective” RTK inhibitors, such as sunitinib malate, has
demonstrated good antitumor efficacy in animal models and in
patients by causing tumor vessel regression through inducing EC
apoptosis [28]. In a previous study, we also demonstrated that 1B3
antibody significantly enhanced the antitumor and the antiangiogenic
activity of an anti-VEGFR2 antibody, DC101, in xenograft models
[16]. In the current study, we evaluated the ability of IMC-2C5 anti-
body in potentiating the antitumor activity of DC101 in various hu-
man tumor xenografts. Consistent with our observation with 1B3, in
three of six xenograft models tested, the IMC-2C5/DC101 combi-
nation was significantly more efficacious than DC101 alone (given
at the optimum dose), whereas IMC-2C5 by itself only had a mod-
est antitumor effect (NCI-H460 model) or no effect at all (BxPC-3
and HCT-116 models). The combination of IMC-2C5 and DC101
also led to a greater tumor inhibition in three other models tested,
albeit the difference did not reach statistical significance when com-
pared with DC101 alone. Similarly, addition of IMC-2C5 to DC101/
chemotherapy combinations also demonstrated an additional antitu-
mor activity.
Because pericyte recruitment to coat nascent vessels during angio-
genesis is essential for the stabilization and further establishment of
Figure 6. IMC-2C5 has an additive effect to DC101/chemotherapy in xenograft models. Athymic nude mice bearing xenografted tumors
of 350 to 400 mm3 size were randomized and divided into four treatment groups (n = 12 per group) and were treated by i.p. injections
three times a week with USP saline, DC101 (40 mg/kg), or IMC-2C5 plus DC101 (40 mg/kg each). Chemotherapy drugs were dosed i.p.
once a week, which started 1 day before the antibody treatment as indicated. (A) NCI-H460 and paclitaxel at 20 mg/kg. (B) MIA-PaCa-2
and gemcitabine at 500 mg/kg. Results shown are the mean ± SEM.
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the vascular network, vessels lacking adequate pericyte coverage are
more vulnerable to VEGF inhibition [4,22]. In a previous study,
we showed that 1B3 treatment alone significantly reduced matured
vessel density (CD31+/αSMA+) compared with the control group,
whereas the total CD31+ vessels of the 1B3 group were not affected,
indicating that PDGFRβ+ pericytes were selectively inhibited [16].
Furthermore, addition of 1B3 to DC101 treatment led to a signifi-
cantly more drastic reduction of vessel density compared with DC101
alone. This was in consistency with an earlier report showing that
combination treatment with imatinib and metronomic chemotherapy
significantly reduced pericyte coverage on tumor vessels [23], leading
to decreased percentage of pericyte-covered mature vessels. In this
study, we demonstrated that the PDGFRβ inhibition not only de-
creased PDGFRβ expression (data not shown) but also attenuated the
expression of VEGF and bFGF elevated by VEGFR2 inhibition. Sev-
eral different effects on tumor stroma by a PDGFRβ antagonist, such
as imatinib, have also been demonstrated. Imatinib relieved interstitial
hypertension and increased tumor uptake of chemotherapy, which
led to enhance the antitumor effects of chemotherapy in KAT-4 and
PROb tumors [42]. In anNSCLC, A549 xenograft, imatinib treatment
resulted in a significant reduction of p-PDGFRβ and VEGF expres-
sion, which in turn reduced tumor vessel density, interstitial fluid pres-
sure, and improved tumor oxygenation [43]. Recently, Kim et al. [40]
showed that imatinib sensitized PDGFRβ-expressing tumor-associated
ECs to chemotherapy in a chemoresistant tumor model, PC-3MM2-
MDR, and led to apoptosis of the ECs in bone lesions. In addition,
multiple abnormalities in various tumor tissues have been reported,
including the relationship between ECs and pericytes, endothelial
sprouting, and altered expression of marker proteins, possibly depend-
ing on different contexts of tumors [6,44]. Taken together, these obser-
vations indicate the complex mechanisms of targeting PDGFRβ in
cancer treatment.
In summary, here we produced a fully human antagonistic anti-
PDGFRβ antibody, IMC-2C5, and demonstrated that the antibody
could significantly enhance the antitumor activity of DC101, an anti-
body directed against VEGFR2, and further inhibit tumor growth
when in combination with DC101 plus chemotherapy in various
tumor xenograft models. In addition, we demonstrated that adding
IMC-2C5 led to the attenuation of the expression of several tumor-
associated growth factors elevated by DC101 before a significant
inhibition of the combination therapy was achieved compared with
DC101 treatment alone. A number of previous studies have shown
that PDGFRβ inhibition could also provide additive/synergistic anti-
tumor activity to a number of chemotherapeutic agents [13,42,45] as
well as selective kinase inhibitors including those to VEGFR2 kinase
[13,28,30]. The enhanced antitumor effect usually correlates well
with the increase in tumor uptake of the concurrently administered
cytotoxic agents, a benefit that likely resulted from the reduction of
interstitial fluid pressure in tumor after treatment with PDGFRβ an-
tagonist [42,46]. Further, coinhibition of PDGFRβ activity has been
shown to increase antitumor efficacy of radiotherapy [47,48]. Taken
together, all these findings should lend great support to use PDGFRβ
antagonists in combination with other antitumor and/or antiangio-
genic agents in the treatment of a broad range of human cancers [49].
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